The rate of severe events for COVID-19 with malignant cancer patients was 33.33% (1689/5068), while the rate of severe events for all patients of COVID-19 was 16.09% (11404/70874) (Table 3), which is significantly higher for malignant patients with COVID-19 disease (33.33% vs 16.09%, p<0.01), suggesting overexpression of HSPA5 might contribute to the severity of COVID-19 patients. This evidence concerns the gene HSPA5 and COVID-19.